Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Celumigen Pharmaceuticals United States

Celumigen Pharmaceuticals is a California- headquartered seed stage specialty pharmaceutical company in dermatology focused on developing the first FDA-approved topical prescription immunotherapeutic drug for Cutaneous viral warts; a widespread global disease affecting greater than 500MM people in China, and 78% of the world's population. The global markets have seen no approved prescription therapies for HPV, Common warts and no therapies that eradicate this disease on the market or in the pipeline-- we plan to capture and grow this lucrative market. Our therapeutic is a likely 505 (b) 2 FDA designated drug. Our leadership, development and clinical team is a group of world class leaders with deep industry knowledge and unparalleled domain expertise. We have raised a seed round led by industry- leading investors which funded a Proof of Concept study with very positive confirmatory results and data to support our Phases I and Phase II. We are now seeking strategic partnership with a company seeking to support drug development to enhance existing dermatology drug asset portfolios or fund our program through venture capital / partnership.
Website:
celumigen.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Strategic investment/ partnership
Headquartner in China
No
Biotech/Pharma Category
Jake Townsend
CEO 

Charnwood Molecular Ltd United Kingdom

Charnwood Molecular is an award-winning, UK-based CRO, which has been providing expert synthetic chemistry support for over 20 years. At Charnwood Molecular, we work with clients of all shapes, sizes and global standing. These range across a variety of sectors, from virtual start-ups to established global agrochemical, materials chemistry, diagnostics, biotechnology and pharmaceutical companies. All of our clients benefit from our proactive and open approach, geared towards rapidly advancing projects towards important key decision points and beyond.
Website:
https://www.charnwood-molecular.com/
Company Size (Fulltime employees)
51-200
Year of foundation
1998
Partnering Objectives
Please specify your partnering goal
Looking for clients
Headquartner in China
No
Biotech/Pharma Category
Dr. Aji Thomas
Business Development Executive 

China Grand Pharm China

HKEX list company，focusing on cardiovascular，biotechologic，ophthmalogic，oncologic，antibiotic and antivirus medicines and cardiovascular devices
Website:
www.chinageandpharm.com
Partnering Objectives
Headquartner in China
No
Rocky Shao
Executive Director 

Claris Ventures United Kingdom

New VC focused on biotech

Website:
http://www.clarisventures.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Networking
Headquartner in China
No
Dr. Fabio D'Agostino
Venture Partner 
Functionality
Investment

Congo medika

Medical platform who has got a medical application named Congo medika (available on Google playstore) that offer 3 services :medical home care, home delivery of drug and useful health advices
Website:
www.congomedika.com
Company Size (Fulltime employees)
1-10
Year of foundation
2019
Partnering Objectives
Please specify your partnering goal
Business to business
Headquartner in China
No
Dr. Emmanuel Epenge djonga
CEO 
Functionality
Management

Connexin Therapeutics Ltd. United Kingdom

Connexin Therapeutics Ltd. is a UK-based biopharmaceutical company specializing in the Discovery and development,, of drugs targeting connexins, initially for the prevention of vision loss and blindness associated with the eye disease known as glaucoma. While there are a variety of glaucoma subtypes, a common hallmark is the progressive loss of vision due to the gradual cell death in the retina and optic nerve triggered by elevated intraocular pressure. Many drugs are available to reduce intraocular pressure, yet none have been shown to directly protect cells in the retina or optic nerve, and hence prevent them from dying. Thus, vision loss inevitably occurs, even in well-treated patients, and severe vision impairment remains common in these patients.
Connexin Therapeutics raised ~£150,000 in Seed financing in early 2019. These funds are being used to synthesize and test novel small molecules in animal models of glaucoma. Selected results from these studies are presented in this document. These compounds are based on a molecule which has already demonstrated efficacy in mouse models of glaucoma. Thus, these data supplement and extend the work already published.
We are currently raising ~£2,000,000 to expand our synthesis and optimize our lead compounds. After ~8-10 quarters of work we anticipate having a library of patentable compounds which are highly selective for our target, backed by cell and animal data. We may also have a second compound which inhibits a different retinal target for a different set of conditions. Future financing rounds will take one or both leads into formulation development, safety studies, and clinical trials, while also fueling our expansion into other indications with this same mechanism of action.
Website:
https://connexintx.co.uk
Year of foundation
2018
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 6.11MB)
Carlos Velez
CEO 
Functionality
Management

Covate Pharma Singapore

Based Singapore, to partner drug development for US/EU/ASEAN market. Founder background - Pharmacist background with PHD, School of Pharmacy London, UK - Worked in Early drug discover and development @ Novartis-UK , commercial side Manufacturing science and technology MS&T in Novartis - Singapore and - Global technical operations -GTO, MSD - Singapore; Drug Device combination products. - Involved in successful filing of several INDs applied the concepts to drug development in a virtual small Biotech, to prepare for Phase 3 clinical trials Partnering objectives - Partner with likeminded companies to address the challenges posed by Covid-19 pandemic - Entrepreneurship, Start-ups, Joint ventures, Fundraising Primary area of expertise Drug Development, IND, NDA, Process validation, CMC, Technology transfer, Digital medicines, Digital Therapies, Entrepreneurship

Website:
in progress
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Drug development
Headquartner in China
No
Biotech/Pharma Category
Slides Deck
(pdf, 493.71KB)
Dr. Ameet Ambarkhane
Director 

Creacion Ventures China

Creacion Ventures is an USD fund of 150million, set up in 2020, focusing on investing cross border biotech companies. We spin off from 6 Dimensions.
Website:
NM
Partnering Objectives
Headquartner in China
No
Kathy Kang
associate 

Crinetics Pharmaceuticals United States

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Website:
https://crinetics.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Business Development
Headquartner in China
No
Biotech/Pharma Category
Mr. Greg Solis
Business Strategy Associate 
Functionality
Business Development

Crossject USA Inc United States

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your Licensing-in strategy and how we might work together.

Website:
www.crossject.com
Year of foundation
2001
Partnering Objectives
Headquartner in China
No
Assets Information 1
Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis. We also have a Medtech model where we can inject 0.2-0.7ml of your drug (small or large molecule) IM or SQ.
Biotech/Pharma Asset Stage
Medtech Category
Medtech Information 1
needle free auto-injector
Medtech Development Stage
Don Zinn
VP US Business 
Functionality
Business Development